Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

LEXICON PHARMACEUTICALS, INC. Director's Dealing 2022

Feb 28, 2022

32814_dirs_2022-02-28_93a3d456-9d27-457f-854f-005fdd2e79c2.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK: 0001062822
Period of Report: 2022-02-28

Reporting Person: Seth Kiernan (VP, Chief Commercial Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-02-28 Common Stock M 10007 Acquired 10007 Direct
2022-02-28 Common Stock M 14834 Acquired 24841 Direct
2022-02-28 Common Stock M 5287 Acquired 30128 Direct
2022-02-28 Common Stock F 8261 $2.85 Disposed 21867 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-02-28 Restricted Stock Units $ M 10007 Disposed Common Stock (10007) Direct
2022-02-28 Restricted Stock Units $ M 14834 Disposed Common Stock (14834) Direct
2022-02-28 Restricted Stock Units $ M 5287 Disposed Common Stock (5287) Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of common stock.

F2: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.

F3: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2020 and vest an additional one third on February 28 of each of the two succeeding years thereafter.

F4: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.